Literature DB >> 33257619

The shortcomings of tocilizumab in COVID-19.

Raghavendra Tirupathi1, Kavya Bharathidasan2, Swetha Areti3, Jagdeep Kaur4, Sohail Salim5, Jaffar A Al-Tawfiq6.   

Abstract

Not available.

Entities:  

Year:  2020        PMID： 33257619

Source DB:  PubMed          Journal:  Infez Med        ISSN： 1124-9390


× No keyword cloud information.
  3 in total

Review 1.  Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review.

Authors:  Thoyaja Koritala; Vishwanath Pattan; Raghavendra Tirupathi; Ali A Rabaan; Abbas Al Mutair; Saad Alhumaid; Ramesh Adhikari; Keerti Deepika; Nitesh Kumar Jain; Vikas Bansal; Aysun Tekin; Simon Zec; Amos Lal; Syed Anjum Khan; Juan Pablo Domecq Garces; Omar M Abu Saleh; Salim R Surani; Rahul Kashyap
Journal:  Infez Med       Date:  2021-12-10

2.  A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital.

Authors:  Salma AlBahrani; Jaffar A Al-Tawfiq; Abdulaziz R Alshaer; Amal Shilash; Khalid Alswefy; Razan Salamah Al-Zayer; Amr Mohamed Abouelela
Journal:  J Epidemiol Glob Health       Date:  2021-01-22

3.  Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.

Authors:  Timothy Arthur Chandos Snow; Naveed Saleem; Gareth Ambler; Eleni Nastouli; Mervyn Singer; Nishkantha Arulkumaran
Journal:  Intensive Care Med       Date:  2021-05-21       Impact factor: 17.440
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.